Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2014

Open Access 01-12-2014 | Research

Clinical efficacy of Enzyme Replacement Therapy in paediatric Hunter patients, an independent study of 3.5 years

Authors: Rosella Tomanin, Alessandra Zanetti, Francesca D’Avanzo, Angelica Rampazzo, Nicoletta Gasparotto, Rossella Parini, Antonia Pascarella, Daniela Concolino, Elena Procopio, Agata Fiumara, Andrea Borgo, Anna Chiara Frigo, Maurizio Scarpa

Published in: Orphanet Journal of Rare Diseases | Issue 1/2014

Login to get access

Abstract

Background

Hunter Syndrome is an X-linked lysosomal storage disorder due to the deficit of iduronate 2-sulfatase, an enzyme catalysing the degradation of the glycosaminoglycans (GAG) dermatan- and heparan-sulfate. Treatment of the disease is mainly performed by Enzyme Replacement Therapy (ERT) with idursulfase, in use since 2006. Clinical efficacy of ERT has been monitored mainly by the Hunter Outcome Survey (HOS) while very few independent studies have been so far conducted. The present study is a 3.5-years independent follow-up of 27 Hunter patients, starting ERT between 1.6 and 27 years of age, with the primary aim to evaluate efficacy of the therapy started at an early age (<12 years).

Methods

In this study, we evaluated: urinary GAG content, hepato/splenomegaly, heart valvulopathies, otorinolaryngological symptoms, joint range of motion, growth, distance covered in the 6-minute walk test, neurological involvement. For data analysis, the 27 patients were divided into three groups according to the age at start of ERT: ≤5 years, >5 and ≤ 12 years and > 12 years. Patients were analysed both as 3 separate groups and also as one group; in addition, the 20 patients who started ERT up to 12 years of age were analysed as one group. Finally, patients presenting a 'severe' phenotype were compared with "attenuated" ones.

Results

Data analysis revealed a statistically significant reduction of the urinary GAG in patients ≤5 years and ≤ 12 years and of the hepatomegaly in the group aged >5 and ≤ 12 years. Although other clinical signs improved in some of the patients monitored, statistical analysis of their variation did not reveal any significant changes following enzyme administration. The evaluation of ERT efficacy in relation to the severity of the disease evidenced slightly higher improvements as for hepatomegaly, splenomegaly, otological disorders and adenotonsillar hypertrophy in severe vs attenuated patients.

Conclusions

Although the present protocol of idursulfase administration may result efficacious in delaying the MPS II somatic disease progression at some extent, in this study we observed that several signs and symptoms did not improve during the therapy. Therefore, a strict monitoring of the efficacy obtained in the patients under ERT is becoming mandatory for clinical, ethical and economic reasons.
Appendix
Available only for authorised users
Literature
1.
Beck M, Wijburg FA, Gal A: Clinical utility gene card for: mucopolysaccharidosis type II. Eur J Hum Genet. 2012, 20: 1-10.1038/ejhg.2011.143. doi:10.1038/ejhg.2011.143. Epub 2011 Aug 24,CrossRef
2.
Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Munoz V, Muenzer J: Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics. 2008, 121 (2): e377-e386. 10.1542/peds.2007-1350.CrossRefPubMed
3.
Neufeld EF, Muenzer J, et al: The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease. Edited by: Scriver CR, Beaudet AL, Sly WS. 2001, McGraw-Hill, New York, NY, USA, 3421-3452. 8
4.
Young ID, Harper PS, Newcombe RG, Archer IM: A clinical and genetic study of Hunter's syndrome. 2. Differences between the mild and severe forms. J Med Genet. 1982, 19 (6): 408-411. 10.1136/jmg.19.6.408.CrossRefPubMedPubMedCentral
5.
Manara R, Priante E, Grimaldi M, Santoro L, Astarita L, Barone R, Concolino D, Di Rocco M, Donati MA, Fecarotta S, Ficcadenti A, Fiumara A, Furlan F, Giovannini I, Lilliu F, Mardari R, Polonara G, Procopio E, Rampazzo A, Rossi A, Sanna G, Parini R, Scarpa M: Brain and spine MRI features of Hunter disease: frequency, natural evolution and response to therapy. J Inherit Metab Dis. 2011, 34 (3): 763-780. 10.1007/s10545-011-9317-5.CrossRefPubMed
6.
Coppa GV, Gabrielli O, Zampini L, Jetzequel AM, Miniero R, Busca A, De Luca T, Di Natale P: Bone marrow transplantation in Hunter syndrome. J Inherit Metab Dis. 1995, 18 (1): 91-92. 10.1007/BF00711387.CrossRefPubMed
7.
Guffon N, Bertrand Y, Forest I, Fouilhoux A, Froissart R: Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr. 2009, 154 (5): 733-737. 10.1016/j.jpeds.2008.11.041.CrossRefPubMed
8.
Muenzer J: Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab. 2014, 111 (2): 63-72. 10.1016/j.ymgme.2013.11.015.CrossRefPubMed
9.
Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, Vellodi A, Martin R, Ramaswami U, Gucsavas-Calikoglu M, Vijayaraghavan S, Wendt S, Puga AC, Ulbrich B, Shinawi M, Cleary M, Piper D, Conway AM, Kimura A: A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006, 8 (8): 465-473. 10.1097/01.gim.0000232477.37660.fb.CrossRefPubMed
10.
Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A: A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007, 90 (3): 329-337. 10.1016/j.ymgme.2006.09.001.CrossRefPubMed
11.
Alcalde-Martin C, Muro-Tudelilla JM, Cancho-Candela R, Gutierrez-Solana LG, Pintos-Morell G, Marti-Herrero M, Munguira-Aguado P, Galan-Gomez E: First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS). Eur J Med Genet. 2010, 53 (6): 371-377. 10.1016/j.ejmg.2010.07.013.CrossRefPubMed
12.
Muenzer J, Beck M, Giugliani R, Suzuki Y, Tylki-Szymanska A, Valayannopoulos V, Vellodi A, Wraith JE: Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet Med. 2011, 13 (2): 102-109. 10.1097/GIM.0b013e318206786f.CrossRefPubMed
13.
Giugliani R, Hwu WL, Tylki-Szymanska A, Whiteman DA, Pano A: A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy. Genet Med. 2014, 16 (6): 435-441. 10.1038/gim.2013.162.CrossRefPubMedPubMedCentral
14.
Lampe C, Atherton A, Burton BK, Descartes M, Giugliani R, Horovitz DD, Kyosen SO, Magalhaes TS, Martins AM, Mendelsohn NJ, Muenzer J, Smith LD: Enzyme Replacement Therapy in Mucopolysaccharidosis II Patients Under 1 Year of Age.JIMD Rep 2014, Epub ahead of print.,
15.
Wyatt K, Henley W, Anderson L, Anderson R, Nikolaou V, Stein K, Klinger L, Hughes D, Waldek S, Lachmann R, Mehta A, Vellodi A, Logan S: The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess. 2012, 16 (39): 1-543.CrossRefPubMed
16.
17.
Clopper CJ, Pearson ES: The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934, 26: 404-10.1093/biomet/26.4.404.CrossRef
18.
Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, Weissman NJ: Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003, 16 (7): 777-802. 10.1016/S0894-7317(03)00335-3.CrossRefPubMed
19.
Cole TJ, Green PJ: Smoothing reference centile curves: the LMS method and penalized likelihood. Stat Med. 1992, 11 (10): 1305-1319. 10.1002/sim.4780111005.CrossRefPubMed
20.
Lammers AE, Hislop AA, Flynn Y, Haworth SG: The 6-minute walk test: normal values for children of 4-11 years of age. Arch Dis Child. 2008, 93 (6): 464-468. 10.1136/adc.2007.123653.CrossRefPubMed
21.
Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, Ramaswami U, Vellodi A, Wraith JE, Cleary M, Gucsavas-Calikoglu M, Puga AC, Shinawi M, Ulbrich B, Vijayaraghavan S, Wendt S, Conway AM, Rossi A, Whiteman DA, Kimura A: Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011, 13 (2): 95-101. 10.1097/GIM.0b013e3181fea459.CrossRefPubMed
22.
Scarpa M: Mucopolysaccharidosis Type II. GeneReviews. Edited by: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP. 1993, University of Washington, Seattle, Seattle (WA)
23.
Scarpa M, Almassy Z, Beck M, Bodamer O, Bruce IA, De Meirleir L, Guffon N, Guillen-Navarro E, Hensman P, Jones S, Kamin W, Kampmann C, Lampe C, Lavery CA, Teles EL, Link B, Lund AM, Malm G, Pitz S, Rothera M, Stewart C, Tylki-Szymanska A, Van der Ploeg A, Walker R, Zeman J, Wraith JE: Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011, 6: 72-1172. 10.1186/1750-1172-6-72.CrossRefPubMedPubMedCentral
24.
Glamuzina E, Fettes E, Bainbridge K, Crook V, Finnegan N, Abulhoul L, Vellodi A: Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points. J Inherit Metab Dis. 2011, 34 (3): 749-754. 10.1007/s10545-011-9280-1.CrossRefPubMed
25.
Kampmann C, Beck M, Morin I, Loehr JP: Prevalence and characterization of cardiac involvement in Hunter syndrome. J Pediatr. 2011, 159 (2): 327-331. 10.1016/j.jpeds.2011.01.054. e2CrossRefPubMed
26.
Fesslova V, Corti P, Sersale G, Rovelli A, Russo P, Mannarino S, Butera G, Parini R: The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young. 2009, 19 (2): 170-178. 10.1017/S1047951109003576.CrossRefPubMed
27.
Brands MM, Frohn-Mulder IM, Hagemans ML, Hop WC, Oussoren E, Helbing WA, van der Ploeg AT: Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI. J Inherit Metab Dis. 2013, 36 (2): 227-234. 10.1007/s10545-011-9444-z.CrossRefPubMedPubMedCentral
28.
Schwartz IV, Ribeiro MG, Mota JG, Toralles MB, Correia P, Horovitz D, Santos ES, Monlleo IL, Fett-Conte AC, Sobrinho RP, Norato DY, Paula AC, Kim CA, Duarte AR, Boy R, Valadares E, De Michelena M, Mabe P, Martinhago CD, Pina-Neto JM, Kok F, Leistner-Segal S, Burin MG, Giugliani R: A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr Suppl. 2007, 96 (455): 63-70. 10.1111/j.1651-2227.2007.00212.x.CrossRef
29.
Rozdzynska A, Tylki-Szymanska A, Jurecka A, Cieslik J: Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II. Acta Paediatr. 2011, 100 (3): 456-460. 10.1111/j.1651-2227.2010.02060.x.CrossRefPubMed
30.
Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J: Initial report from the Hunter Outcome Survey. Genet Med. 2008, 10 (7): 508-516. 10.1097/GIM.0b013e31817701e6.CrossRefPubMed
31.
Jones SA, Parini R, Harmatz P, Giugliani R, Fang J, Mendelsohn NJ: The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2013, 109 (1): 41-48. 10.1016/j.ymgme.2013.03.001.CrossRefPubMed
32.
Marucha J, Jurecka A, Syczewska M, Rozdzynska-Swiatkowska A, Tylki-Szymanska A: Restricted joint range of motion in patients with MPS II: correlation with height, age and functional status. Acta Paediatr. 2012, 101 (4): e183-e188. 10.1111/j.1651-2227.2011.02522.x.CrossRefPubMed
33.
Da Silva EM, Strufaldi MW, Andriolo RB, Silva LA: Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). Cochrane Database Syst Rev. 2011, 11 (11): CD008185-PubMed
34.
Da Silva EM, Strufaldi MW, Andriolo RB, Silva LA: Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). Cochrane Database Syst Rev. 2014, 1: CD008185-PubMed
35.
Holt JB, Poe MD, Escolar ML: Natural progression of neurological disease in mucopolysaccharidosis type II. Pediatrics. 2011, 127 (5): e1258-e1265. 10.1542/peds.2010-1274.CrossRefPubMed
36.
Muenzer J, Beck M, Eng CM, Escolar ML, Giugliani R, Guffon NH, Harmatz P, Kamin W, Kampmann C, Koseoglu ST, Link B, Martin RA, Molter DW, Munoz Rojas MV, Ogilvie JW, Parini R, Ramaswami U, Scarpa M, Schwartz IV, Wood RE, Wraith E: Multidisciplinary management of Hunter syndrome. Pediatrics. 2009, 124 (6): e1228-e1239. 10.1542/peds.2008-0999.CrossRefPubMed
37.
Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, Meldgaard Lund A, Malm G, Van der Ploeg AT, Zeman J: Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008, 167 (3): 267-277. 10.1007/s00431-007-0635-4.CrossRefPubMedPubMedCentral
38.
Roos JC, Hyry HI, Cox TM: Orphan drug pricing may warrant a competition law investigation. BMJ. 2010, 341: c6471-10.1136/bmj.c6471.CrossRefPubMed
39.
Simoens S: Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011, 6 (42): 1172-1176.
40.
Muenzer J, Bodamer O, Burton B, Clarke L, Frenking GS, Giugliani R, Jones S, Rojas MV, Scarpa M, Beck M, Harmatz P: The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. Eur J Pediatr. 2012, 171 (1): 181-188. 10.1007/s00431-011-1606-3.CrossRefPubMedPubMedCentral
Metadata
Title
Clinical efficacy of Enzyme Replacement Therapy in paediatric Hunter patients, an independent study of 3.5 years
Authors
Rosella Tomanin
Alessandra Zanetti
Francesca D’Avanzo
Angelica Rampazzo
Nicoletta Gasparotto
Rossella Parini
Antonia Pascarella
Daniela Concolino
Elena Procopio
Agata Fiumara
Andrea Borgo
Anna Chiara Frigo
Maurizio Scarpa
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2014
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-014-0129-1

Other articles of this Issue 1/2014

Orphanet Journal of Rare Diseases 1/2014 Go to the issue

Research

Expanding the phenotype of PRPS1 syndromes in females: neuropathy, hearing loss and retinopathy

Review

Clinical spectrum and long-term follow-up of 14 cases with G6PC3 mutations from the French severe congenital neutropenia registry

Letter to the Editor

Concerns about unapproved meningococcal vaccination for eculizumab therapy in Japan

Editorial

The European Union Committee of Experts on Rare Diseases: three productive years at the service of the rare disease community

Research

Sudden unexpected fatal encephalopathy in adults with OTC gene mutations-Clues for early diagnosis and timely treatment

Research

Oxidative stress and mitochondrial dysfunction in Kindler syndrome